Table 1.

Characteristics of patients on olaparib capsule and placebo maintenance therapy—Study 19

Clinical statusBRCA status
Treatment durationNumber of lines of prior chemotherapy [median (range)]Initial FIGO state (n pts)RECIST at baseline (n)Platinum sensitivity status (n)BRCAm (n = 74)BRCA WT (n = 57)BRCA missing (n = 5)
Olaparib arm (n = 136)
ST responders: <3 months2.8 (2–5)1II/19III/1IVPR: 166–12 months: 910 (14%)9 (16%)2
 21 pts (15%)CR: 512 months: 127 BRCA1
LT responders: >2 years2.9 (2–8)3I/II25III/3IVPR: 146–12 months: 1122 (30%)10 (18%)0
 32 pts (24%)Missing: 1CR: 18>12 months: 2110 BRCA1
Placebo arm (n = 129)
ST responders: <3 months2.8 (2–8)3I/II27III/8IVPR: 256–12 months: 2219 (31%)18 (30%)3
 40 pts (31%)Missing: 2CR: 15>12 months: 1816 BRCA1
LT responders: >2 years2 (2)5 IIIPR: 16–12 months: 15 (8%)00
 5 pts (4%)CR: 4>12 months: 44 BRCA1
  • Abbreviations: CR, complete response; FIGO, International Federation of Gynecology and Obstetrics; PR, partial response; pts, patients; WT, wild-type